Results 61 to 70 of about 1,394,911 (165)

Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

American Journal of Hematology, Volume 101, Issue 11, Page 2836-2852, November 2026.
ABSTRACT Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation.
Matthieu Mahévas, Nichola Cooper, Vickie McDonald, Karina Yazdanbakhsh, Wilma Barcellini   +4 more
wiley   +1 more source

Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage

Platelets, 2017
We present here a 63-year old woman with a long history of immune thrombocytopenia. She was hospitalized for a traumatic intracranial hemorrhage with thrombocytopenia.
O. Espitia, C. Ternisien, C. Agard, P. Boisseau, C. V. Denis, M. Fouassier   +5 more
doaj   +1 more source

Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG‐2015 French Innovative Leukemia Organization phase 2 randomized trial

Cancer, Volume 132, Issue 21, 1 November 2026.
Abstract Background Elderly patients with acute myeloid leukemia (AML) treated with intensive chemotherapy are at risk of developing thrombopenia, which requires platelet transfusions. It would be interesting to provide them with thrombopoietin receptor agonists such as eltrombopag.
Arnaud Pigneux, Pierre‐Yves Dumas, Marc Bernard, Norbert Vey, Audrey Bidet, Ariane Mineur, Aline Schmidt, Martin Carré, Mario Ojeda, Sarah Bertoli, Anne Banos, Pierre Peterlin, Romain Guièze, Yohan Desbrosses, Gabrielle Roth Guepin, Célestine Simand, Thibaut Leguay, Emmanuel Gyan, Eric Jourdan, Jean‐Philippe Vial, Tony Marchand, Yosr Hicheri, Marie C. Béné, Jean Francois Hamel, Christian Récher   +24 more
wiley   +1 more source

Soluble Thrombopoietin Receptor Fragments and Uses Thereof

, 2023
The present invention relates to a polypeptide comprising the extracellular domain of the thrombopoietin receptor or fragments thereof, and its use as a medicament.
Université Catholique de Louvain, Constantinescu, Stefan N., Nedelec, Audrey, Papadopoulos, Nicolas   +3 more
core  

Impact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC

HemaSphere, Volume 10, Issue 11, November 2026.
Abstract The impact of venetoclax‐based therapies on autoimmune cytopenias (AIC) in patients with chronic lymphocytic leukemia (CLL) is largely unknown. This study aimed to evaluate preexisting and treatment‐emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax‐based ...
Candida Vitale, Thomas Chatzikonstantinou, Christina Papangelou, Francesca Perutelli, Maria Chiara Montalbano, Giulia Bondielli, Elia Boccellato, Salem Alshemmari, Francesco Angotzi, Miguel Arguello‐Tomas, Tomas Arpas, Sandra Bašić‐Kinda, Sotiria Besikli‐Dimou, Łukasz Bołkun, Tomasz Buczek, Aleksandra Butrym, Katherine Chapis, Sofia Chatzileontiadou, Rosa Collado, Raul Cordoba Mascuñano, Lorenzo De Paoli, Marina Deodato, Maria Dimou, David Donaldson, Joanna Drozd‐Sokołowska, Salem Elias, Andrea Ferrario, Alberto Fresa, Anna Maria Frustaci, Rocío García‐Serra, Ajay Gogia, Isabel González‐Gascón‐y‐Marín, Vasko Graklanov, Maria Hryniewiecka, Zhu Huayuan, Elzbieta Iskierka‐Jażdżewska, Paula Jablonowska‐Babij, Ozren Jaksic, Elzbieta Kalicińska, Maria Kislova, Maya Koren‐Michowitz, Epameinondas Koumpis, Zuzana Kubová, Jorge Labrador, Pietro Lauzzana, Shai Levi, Francesca Martini, Mariia Mikhaleva, Eva Minga, Riccardo Moia, Elżbieta Morawiec‐Szymonik, Marta Morawska, Femke V. M. Mulder, Roberta Murru, Jacopo Olivieri, Ewa Paszkiewicz‐Kozik, Lata Rani, Josep Maria Roncero, Wojciech Salamon, Alessandro Sanna, Lydia Scarfò, Tereza Shokralla, Martin Šimkovič, Matevž Škerget, Emil Spasov, Antigoni Tranidou, Jagoda Tryc‐Szponder, Marzia Varettoni, Andrea Visentin, George Vrachiolias, David Waddell, Ewa Wasik‐Szczepanek, Kamil Wdowiak, Mateusz Wilk, Kamil Wiśniewski, Magdalena Witkowska, Mohamed Yassin, Seyma Yıldız, Klaudia Zielonka, Nil Albiol, Jennifer R. Brown, Benedetto Bruno, Mark Catherwood, Anastasia Chatzidimitriou, Michael Doubek, Gianluca Gaidano, Alessandro Gozzetti, Ritu Gupta, Eleftheria Hatzimichael, Yair Herishanu, Krzysztof Jamroziak, Ioannis Kotsianidis, Luca Laurenti, Eugene Nikitin, Maria Papaioannou, Tomáš Papajik, Martin Špaček, Niki Stavroyianni, Josephine M. I. Vos, Tomasz Wróbel, Münci Yağcı, Arnon P. Kater, Matthew Davids, Petra Langerbeins, Kostas Stamatopoulos, Paolo Ghia, Marta Coscia   +106 more
wiley   +1 more source

Thrombopoietin receptor agonists in hereditary thrombocytopenias

, 2018
Hereditary thrombocytopenias (HTPs) constitute a heterogeneous group of diseases characterized by a reduction in platelet count and a potential bleeding risk.
Rodeghiero, F., Pecci, A., Balduini, C. L.   +2 more
core   +1 more source

Cryo-EM structure of the extracellular domain of murine Thrombopoietin Receptor in complex with Thrombopoietin

Thrombopoietin (Tpo) is the primary regulator of megakaryocyte and platelet numbers and is required for haematopoetic stem cell maintenance. Tpo functions by binding its receptor (TpoR, a homodimeric Class I cytokine receptor) and initiating cell ...
Josephine Iaria, Leila Jebeli, Nicos A. Nicola, Kaiseal T. G. Sarson-Lawrence, Nichollas E. Scott, Tamanna Saiyed, Kira Behrens, Nadia J. Kershaw, Cyrus Tan, Andrew P. Leis, Jeffrey J. Babon, Dina Stockwell, Joshua M. Hardy, Toby A. Dite, Tan, C, Babon, JJ, Behrens, K, Sarson-Lawrence, KTG, Jebeli, L, Leis, AP, Dite, TA, Stockwell, D, Iaria, J, Saiyed, T, Scott, NE, Nicola, NA, Kershaw, NJ, Hardy, JM   +27 more
core   +2 more sources

Novel Perspectives on Thrombopoietin Receptor Agonists Applications

, 2023
Second-generation thrombopoietin receptor agonists (TPO-RAs), romiplostim, eltrombopag, and avatrombopag, have been proved to be significant stimulators of megakaryopoiesis and, in the last decade, they have been incorporated in the treatment options ...
Chatzidavid, Sevastianos, Syriopoulou, Stavroula, Vlachopoulou, Dimitra, Viniou, Nora-Athina, Stafylidis, Christos   +4 more
core  

Safety, Pharmacokinetics, and Efficacy Study of Porcine and Rabbit Antithymocyte Globulin in the Treatment of Patients With Severe Aplastic Anemia: A Multicenter, Prospective, Randomized, Open‐Label Clinical Trial

MedComm, Volume 7, Issue 11, November 2026.
This prospective trial compared porcine‐ATG and rabbit‐ATG for severe aplastic anemia. Both agents peaked on Day 5, with faster clearance for rabbit‐ATG. Porcine‐ATG induced an early stable neutrophil rise, whereas rabbit‐ATG caused an initial neutrophil drop.
Yawen Zhang, Yingying Zhang, Yuemin Gong, Yu Sun, Guangsheng He   +4 more
wiley   +1 more source

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation [PDF]

, 2016
Somatic mutations in calreticulin (CALR) are present in approximately 40% of patients with myeloproliferative neoplasms (MPN), but the mechanism by which mutant CALR is oncogenic remains unclear.
Schneider, RK, Losman, JA, Perales-Patón, J., Tothova, Z., Peskier, F., Mullally, A., Losman, J.A., Giannini, S, Al-Shahrour, F, Chen, E, Rosen, EA, Chen, E., Al-Shahrour, F., Giannini, S., Ko, A, Elf, S, Abdelfattah, N.S., Wolach, O., Morgan, E.A., Schneider, R.K., Florescu, N, Mullally, A, Elf, S., Florescu, N., Wolach, O, Morgan, EA, Ko, A., Peisker, F, Perales-Patón, J, Tothova, Z, Abdelfattah, NS, Rosen, E.A.   +31 more
core   +1 more source